Khurram Wadud, MD
Endocrinology, Diabetes & Metabolism · Jacksonville, FLNPI 1801877576
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $53,415 of the $76,937 with a category attached, or 69.4%. 50 manufacturers reported payments, led by Bayer at 37.2% of the total. Reporting peaked in 2019 at $19,498 and has fallen 83.9% since, to $3,143 in 2025. Among endocrinology, diabetes & metabolism clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,096 payments — averaging $70.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$29K
- AstraZeneca$27K
- Novo Nordisk$4K
- Abbott$2K
- Medtronic$1K
- Sanofi-aventis U.S. LLC$1K
- plus $12K from 44 others
Across 886 payments — averaging $294.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$259K
- Janssen Research & Development, LLC$2K
What the payments were for
- Consulting fees$2,0403%
- Speaking & faculty fees$53,41569%
- Travel & lodging$1,4972%
- Food & beverage$19,93226%
- Education$530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$27,807
- FARXIGA$26,410
- RYBELSUS$2,040
- Minimed 670G System$938
- TEPEZZA$272
- CeQur Simplicity$254
- AFREZZA$235
- Omnipod$125
- Saxenda$120
- FreeStyle Libre 2$109
- Synthroid$104
- DEXCOM G6 TRANSMITTER$101
- TWIIST$100
- FreeStyle Libre$100
How this compares
$76,937 in reported general payments places this provider in the 90th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 606 | $1,089,242 |
| MounjaroTirzepatide | 209 | $364,598 |
| JardianceEmpagliflozin | 189 | $248,857 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 162 | $248,088 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 145 | $185,593 |
| FarxigaDapagliflozin Propanediol | 141 | $151,561 |
| Tresiba Flextouch U-200Insulin Degludec | 105 | $126,087 |
| RybelsusSemaglutide | 71 | $122,198 |
| TrulicityDulaglutide | 49 | $81,951 |
| JanuviaSitagliptin Phosphate | 64 | $80,360 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 45 | $78,881 |
| Tresiba Flextouch U-100Insulin Degludec | 86 | $69,070 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 37 | $55,757 |
| GlyxambiEmpagliflozin/Linagliptin | 35 | $54,464 |
| ProliaDenosumab | 30 | $52,821 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $4,174 | $1,243,108754 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,288 | $475,229329 claims |
| Boehringer IngelheimJardiance, Glyxambi, Synjardy Xr, Tradjenta | $966 | $356,613265 claims |
| AstraZenecaFarxiga | $27,485 | $151,561141 claims |
| MerckJanuvia, Janumet Xr | $135 | $97,61685 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $1,394 | $55,75737 claims |
| AmgenProlia | $1,220 | $52,82130 claims |
| AbbVieSynthroid | $375 | $20,710204 claims |
| Amneal Pharmaceuticals LLCUnithroid | $715 | $14,722251 claims |
| Antares Pharma, Inc.Xyosted | $399 | $10,51315 claims |
| Johnson & JohnsonInvokana | $27 | $7,50113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Jacksonville
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
- Wasim DeebJacksonville$286K
- Senan SultanJacksonville$55K
- Firas WardaJacksonville$38K
- Maria Hurtado AndradeJacksonville$36K
- Jay SkylerMiami$2.2M
- Arelis MaderaPort Charlotte$1.7M
- Damon TantonOrlando$1.2M
- Gaston PonteMelbourne$906K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.